Urica Therapeutics Inc.Katy, TX, United States
Business development and drug development specialist
1104: Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial
Monday, November 13, 20239:00 AM – 11:00 AM PT
Disclosure information not submitted.
